Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects

The Journal of clinical investigation (Impact Factor: 13.22). 12/2013; 124(1). DOI: 10.1172/JCI70462
Source: PubMed


Aniridia is a congenital and progressive panocular condition with poor visual prognosis that is associated with brain, olfactory, and pancreatic abnormalities. Development of aniridia is linked with nonsense mutations that result in paired box 6 (PAX6) haploinsufficiency. Here, we used a mouse model of aniridia to test the hypothesis that manipulation of Pax6 dosage through a mutation-independent nonsense mutation suppression strategy would limit progressive, postnatal damage in the eye. We focused on the nonsense suppression drugs 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid (ataluren) and gentamicin. Remarkably, we demonstrated that nonsense suppression not only inhibited disease progression but also stably reversed corneal, lens, and retinal malformation defects and restored electrical and behavioral responses of the retina. The most successful results were achieved through topical application of the drug formulation START (0.9% sodium chloride, 1% Tween 80, 1% powdered ataluren, 1% carboxymethylcellulose), which was designed to enhance particle dispersion and to increase suspension viscosity. These observations suggest that the eye retains marked developmental plasticity into the postnatal period and remains sensitive to molecular remodeling. Furthermore, these data indicate that other neurological developmental anomalies associated with dosage-sensitive genetic mutations may be reversible through nonsense suppression therapeutics.

Download full-text


Available from: Kevin Gregory-Evans, Oct 14, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aniridia is a panocular disorder that severely affects vision in early life. Most cases are caused by dominantly inherited mutations or deletions of the PAX6 gene, which encodes a transcription factor that is essential for the development of the eye and the central nervous system. In this issue of the JCI, Gregory-Evans and colleagues demonstrate that early postnatal topical administration of an ataluren-based formulation reverses congenital malformations in the postnatal mouse eye, providing evidence that manipulation of PAX6 after birth may lead to corrective tissue remodeling. These findings offer hope that ataluren administration could be a therapeutic paradigm applicable to some major congenital eye defects.
    Preview · Article · Dec 2013 · The Journal of clinical investigation
  • [Show abstract] [Hide abstract]
    ABSTRACT: Specific DNA-binding transcription factors (TFs) are critical components of gene regulatory networks (GRNs) that govern lens growth and differentiation. Lens placode formation is controlled by Pax6, Six3, and Sox2. Lens vesicle formation and its separation from the surface ectoderm are regulated by AP-2α, Foxe3, and retinoic acid/retinoid-activated nuclear receptors. The lens precursor cells exit cell cycle via a coordinated action of Gata3, Pitx3, and Prox1. Lens fiber cell differentiation is controlled by ATF4/CREB2, c-Maf, Gata3, Hsf4, Pax6, Pitx3, Prox1, and Sox1. Lens morphogenesis requires intricate temporal and spatial control of gene expression that is executed through multiple links between TFs and extracellular signaling, including BMP, FGF, Notch, and Wnt pathways. Disrupted function of lens-preferred TFs results in multiple lens developmental abnormalities that range from the lack of lens formation, lost of primordial lens (aphakia), incomplete separation of the lens vesicle from the surface ectoderm (corneal-lenticular stalk), disrupted lens fiber cell differentiation, and retention of subcellular organelles including the nuclei. These developmental abnormalities are not compatible with lens transparency and result in congenital cataracts. These cataracts affect 1:2,500 individuals and are difficult to manage due to the age of the child and eye growth considerations, possible associated microcornea or microphthalmia, and risks of glaucoma and amblyopia. For example, up to ~40 % of children with bilateral cataracts develop glaucoma following surgery, particularly when cataracts are removed early in life. This review describes normal and abnormal lens formation through the perspective of TFs preferentially expressed in the lens, their contributions to the human pediatric cataracts, and current strategies in human genetic and clinical studies to identify novel cataract-associated genes to better understand molecular basis of these defects and its treatments.
    No preview · Chapter · Mar 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To highlight major advancements in ocular genetics from the year 2013. Design: Literature review. Methods: A literature search was conducted on PubMed to identify articles pertaining to genetic influences on human eye diseases. This review focuses on manuscripts published in print or online in the English language between January 1, 2013 and December 31, 2013. A total of 120 papers from 2013 were included in this review. Results: Significant progress has been made in our understanding of the genetic basis of a broad group of ocular disorders, including glaucoma, age-related macular degeneration, cataract, diabetic retinopathy, keratoconus, Fuchs' endothelial dystrophy, and refractive error. Conclusions: The latest next-generation sequencing technologies have become extremely effective tools for identifying gene mutations associated with ocular disease. These technological advancements have also paved the way for utilization of genetic information in clinical practice, including disease diagnosis, prediction of treatment response and molecular interventions guided by gene-based knowledge.
    Full-text · Article · May 2014
Show more